Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
$11.51
$6.64
$35.52
$12.87M1.87479,845 shs17,400 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.09
+13.3%
$0.09
$0.06
$0.20
$1.12M0.597,513 shs307 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$0.42
-3.6%
$0.51
$0.16
$2.31
$41.26M0.665.83 million shs8.61 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00%0.00%0.00%0.00%0.00%
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%-3.41%-0.23%+11.40%-55.26%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.00%-7.09%-14.43%+125.50%-74.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
$11.51
$6.64
$35.52
$12.87M1.87479,845 shs17,400 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.09
+13.3%
$0.09
$0.06
$0.20
$1.12M0.597,513 shs307 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$0.42
-3.6%
$0.51
$0.16
$2.31
$41.26M0.665.83 million shs8.61 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00%0.00%0.00%0.00%0.00%
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%-3.41%-0.23%+11.40%-55.26%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.00%-7.09%-14.43%+125.50%-74.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.20
Buy$7.881,794.85% Upside

Current Analyst Ratings Breakdown

Latest DYNT, PSTV, and APOP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
9/3/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
9/3/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$5.00
8/18/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$4.00 ➝ $3.00
6/27/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$5.50 ➝ $3.00
6/25/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$9.00
(Data available from 9/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A$4.77 per shareN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.03N/AN/A$0.57 per share0.15
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/A($1.52) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
-$5.62MN/A0.00N/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$0.78N/AN/A-8.35%-41.81%-9.56%9/22/2025 (Estimated)
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)

Latest DYNT, PSTV, and APOP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
3.01
3.01
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
1.26
1.26

Institutional Ownership

CompanyInstitutional Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
4.84%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
7.98%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
2,020977,000N/ANot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20013.18 million8.11 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2099.27 million98.48 millionNot Optionable

Recent News About These Companies

Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital
Brokerages Set Plus Therapeutics, Inc. (NASDAQ:PSTV) PT at $7.88
Plus Therapeutics Reports $3M in Stock Equity
Plus Therapeutics Reports $3M in Stock Equity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellect Biotechnology stock logo

Cellect Biotechnology NASDAQ:APOP

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

$0.08 +0.01 (+13.33%)
As of 09/19/2025 02:41 PM Eastern

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$0.42 -0.02 (-3.60%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$0.42 +0.00 (+1.06%)
As of 09/19/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.